Ozempic 是一种糖尿病药物，在一项小型研究中显示出减少饮酒和渴望的前景。 Ozempic, a diabetes drug, shows promise in reducing alcohol consumption and cravings in a small study.

一项小型临床试验发现，Ozempic 是一种用于糖尿病和减肥的药物，可显着减少中度酒精使用障碍患者的饮酒和渴望。 A small clinical trial found that Ozempic, a drug used for diabetes and weight loss, significantly reduced alcohol consumption and cravings in individuals with moderate alcohol-use disorder. 这项涉及 48 名参与者的研究显示，与安慰剂组相比，服用 semaglutide（该药物的通用名称）的人饮酒量更少，渴望减少。 The study, involving 48 participants, showed those on semaglutide, the drug's generic name, drank less alcohol and had reduced cravings compared to a placebo group. 虽然前景广阔，但研究人员呼吁进行更大规模、更长时间的研究来证实这些发现并评估长期益处。 While promising, researchers call for larger and longer studies to confirm these findings and assess long-term benefits.